Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan;30(1):78-85.
doi: 10.1002/pds.5165. Epub 2020 Nov 11.

Real world data to identify target population for new CAR-T therapies

Valeria Belleudi  1 , Francesco Trotta  2 , Filomena Fortinguerra  2 , Francesca R Poggi  1 , Odoardo Olimpieri  2 , Enrica Santelli  1 , Ilaria Cozzi  1 , Paola Michelozzi  1 , Antonio Addis  1
Affiliations

Real world data to identify target population for new CAR-T therapies

Valeria Belleudi et al. Pharmacoepidemiol Drug Saf. 2021 Jan.

Abstract

Purpose: Diffuse large B-cell lymphoma (DLBCL) is an aggressive lymphoma often refractory to currently available treatments (immuno-chemotherapy/autologous-stem-cell-transplantation-ASCT). Recently, new cell therapies have been approved for patients failing two conventional treatments, CAR-T (Chimeric-Antigen-Receptor-T-cell), committing payers in planning and implementing their use. We aim to define, using Real World Data (RWD), a reproducible procedure that allows identification of CAR-T target population for DLBCL.

Methods: Through the linking of electronic healthcare datasets (EHD), we identified patients with non-Hodgkin's Lymphoma (NHL), resident in Lazio region (2010-2015), aged ≥20 years. DLBCL patients were followed using pathological anatomy (PA) reports, up to 3 years. To be defined as relapsed after two treatment lines, patients must have had new chemotherapy and/or NHL hospitalization after ASCT or at the end of the second chemotherapy. The incident rate of second relapse (R2-rate) was extended to the population without PA reports.

Result: NHL incident patients were 7384, 68% presented a PA report and, 29% of these had DLBCL codes. Patients who relapsed after two treatment lines were 47 (39%) in the subgroup of patients who received ASCT and 138 (41%) in that with second chemotherapy treatment. Patients in the two subgroups were very different in terms of age and comorbidity. The annual incident number of DLBCL was estimated to be 329 which multiplied by R2-rate (13.7%) gives 45 patients per year eligible for CAR-T.

Discussion: This study shows how RWD allows the identification of a target population with new advanced therapies. This approach is rigorous, transparent and verifiable over time.

Keywords: CAR-T; DLBCL; algorithm; pharmacoepidemiology; real world data; target population; targeted drug development.

PubMed Disclaimer

References

REFERENCES

    1. The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP). Guide on Methodological Standards in Pharmacoepidemiology (Revision 5). EMA/95098/2010. 2010; http://www.encepp.eu/standards_and_guidances. Accessed January 9, 2020.
    1. Cave A, Kurz X, Arlett P. Real-world data for regulatory decision making: challenges and possible solutions for Europe. Clin Pharmacol Ther. 2019;106:36-39. https://doi.org/10.1002/cpt.1426.
    1. The FDA's Real-World Evidence website. Real-world data (RWD) and real-world evidence (RWE) are playing an increasing role in health care decisions. 2020; https://www.fda.gov/science-research/science-and-research-special-topics.... Accessed January 9, 2020.
    1. Guess HA. Premarketing applications of pharmacoepidemiology. In: Strom BL, ed. Pharmacoepidemiology. 3rd ed. New York: Wiley; 2000:450-462:chap 28.
    1. Chow VA, Shadman M, Gopal AK. Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma. Blood. 2018;132:777-781. https://doi.org/10.1182/blood-2018-04-839217.

Publication types

MeSH terms

Substances

LinkOut - more resources